Powered by

VFMCRP and ChemoCentryx Announce Positive Topline Data From Pivotal Phase-III ADVOCATE Trial Demonstrating Avacopan's Superiority Over Standard of Care in ANCA Associated Vasculitis

Nov 26, 2019 - Business Wire

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191125005734/en/

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and ChemoCentryx, Inc., (NASDAQ:CCXI) today announced positive topline data from the pivotal phase-III ADVOCATE trial of avacopan, an orally administered selective complement 5a receptor inhibitor, for the treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (A...